Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

Abstracts Background Although peripheral blood-based parameters (PBBPs) are reported as prognostic indicators in patients with breast cancers, their utility has not been studied in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC). Tumor-infiltrating lymphocytes (...

Full description

Bibliographic Details
Main Authors: Kazuhiro Araki, Yoshinori Ito, Ippei Fukada, Kokoro Kobayashi, Yoshimasa Miyagawa, Michiko Imamura, Ayako Kira, Yuichi Takatsuka, Chiyomi Egawa, Hirofumi Suwa, Shinji Ohno, Yasuo Miyoshi
Format: Article
Language:English
Published: BMC 2018-10-01
Series:BMC Cancer
Subjects:
Absolute lymphocyte counts
Predictive biomarker
Pertuzumab
Trastuzumab
HER2-positive ABC
Host immunity
Online Access:http://link.springer.com/article/10.1186/s12885-018-4888-2

Internet

http://link.springer.com/article/10.1186/s12885-018-4888-2

Similar Items